bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 445 shares, a decline of 85.9% from the August 31st total of 3,162 shares. Based on an average daily volume of 30,259 shares, the days-to-cover ratio is currently 0.0 days.
bioAffinity Technologies Stock Performance
NASDAQ BIAFW opened at $0.29 on Friday. bioAffinity Technologies has a one year low of $0.05 and a one year high of $0.98. The company’s 50 day moving average price is $0.20 and its 200 day moving average price is $0.23.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc is a clinical-stage medical device company developing an extracorporeal immunoadsorption platform intended to treat Gram-negative sepsis and other severe inflammatory conditions. The company’s technology employs specialized sorbent cartridges designed to selectively bind and remove circulating endotoxins and inflammatory mediators from the bloodstream, with the goal of supporting critical care interventions and improving patient outcomes.
In preclinical studies, bioAffinity’s hemoperfusion devices have demonstrated the ability to capture lipopolysaccharides released by Gram-negative bacteria, leading to reductions in pro-inflammatory cytokines and enhanced survival rates in animal models.
See Also
- Five stocks we like better than bioAffinity Technologies
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
